This is a single-center, prospective, randomized controlled trial evaluating type A botulinum toxin injection and prism therapy for the treatment of small-angle acute acquired concomitant esotropia.
Specific Aim 1 (Primary): To compare the reduction of deviation angle and improvement of diplopia symptoms between botulinum toxin injection and prism therapy for the treatment of small-angle acute acquired concomitant esotropia.
Specific Aim 2 (Secondary): To compare the improvement of visual functions between botulinum toxin injection and prism therapy for the treatment of small-angle acute acquired concomitant esotropia.
Eligibility
Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. acute acquired concomitant esotropia diagnosis (sudden onset of esotropia or diplopia, no significant change in the degree of strabismus in each eye position, and no limitation in eye movement)
2. strabismus angle ≤ 25PD
3. best corrected visual acuity of both eyes ≥ 1.0
4. intracranial disease is excluded by cranial CT or magnetic resonance imaging
Exclusion Criteria:
1. reduction of strabismus angle by more than 10 prism diopters after refractive correction
2. history of other ocular diseases or ocular surgeries
3. presence of organic brain lesions or systemic diseases
Primary outcome measure(s)
strabismus angle — Before treatment, 1 week, 1 month, 3 months, 6 months after treatment using prism cover test to evaluate the reduction of strabismus angle
Trial sites (1)
Facility
City
Region
Status
Eye & ENT Hospital of Fudan University
Shanghai
China
More Eye & ENT Hospital of Fudan University trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.